Laboratory requisitions for BPC-157 (5mg / 10mg) fail QA when specification fields are paraphrased. BPC-157 Specification and Vial Format Review maps Repair & Recovery Research catalog data on sulanpeptide.vip.
BPC-157 is a synthetic pentadecapeptide used in laboratory research on repair-signaling pathways, extracellular-matrix remodeling, angiogenesis-related models, and peptide-mediated cellular response mechanisms.
HPLC purity specifications above 98% are typical procurement targets because migration assays are sensitive to peptide degradation products. Croatian and international groups published extensive rodent model work on gastrointestinal lesion models and tendon healing time courses using stable pentadecapeptide preparations.
BPC-157 (Body Protection Compound sequence) is studied for effects on fibroblast migration, F-actin organization, and growth-factor receptor expression in tendon and ligament cell models. Published work explores nitric oxide synthase modulation and VEGF pathway transcripts in wound-healing chamber models—strictly preclinical laboratory contexts.
Scratch-assay migration, collagen gel contraction, and rat tendon transection histology are recurring experimental formats in BPC-157 research literature.
Side-by-side review of specification table, vial label, and COA prevents release errors for BPC-157. Principal investigators should sign off BPC-157 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for BPC-157: CAS 137525-51-0, Formula: C62H98N16O22. MW 1419.5 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Dose planning for BPC-157 should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Publication methods should list Cat No. and mg strength for BPC-157 to support reproducibility.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for BPC-157 should state whether the lot COA must meet or exceed that threshold for your Repair & Recovery Research assay type. Specification alignment for BPC-157 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for BPC-157—CAS 137525-51-0, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing BPC-157 should include these fields for reproducibility in Repair & Recovery Research journals. Format selection for BPC-157 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for BPC-157. QA sign-off should reference all four documents in the batch record.
Format selection for BPC-157 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for BPC-157. QA sign-off should reference all four documents in the batch record.
Molecular identifiers for BPC-157—CAS 137525-51-0, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing BPC-157 should include these fields for reproducibility in Repair & Recovery Research journals.
BPC-157 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.